Obicetrapib
CETP inhibition as a longevity pathway: apoB lowering, not HDL raising, is the mechanism, with signals in diabetes, dementia and kidney disease (Curr Opin Lipidol 2024)
Original title: Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity
A review by trial investigators describing the biological plausibility for CETP inhibition benefiting multiple organ systems through lipoprotein metabolism. Observational studies, Mendelian randomisation and randomised trials support ASCVD risk reduction through lowering apoB-containing lipoproteins, while raising HDL particles alone, the original hypothesis behind the drug class, has not been shown to reduce ASCVD risk. The authors describe an expanding evidence base for CETP inhibition protecting against other ageing-related conditions, particularly new-onset type 2 diabetes and dementia, and possibly age-related macular degeneration, septicaemia and chronic kidney disease, largely mediated through improved HDL particle functionality including cholesterol efflux and antioxidative, anti-inflammatory and antimicrobial activity. The authors call the ASCVD evidence for CETP inhibition robust and the longevity-related benefits plausible but still to be confirmed by the ongoing obicetrapib trial programme.
Original abstract
Purpose Of Review: To review the evidence and describe the biological plausibility for the benefits of inhibiting cholesteryl ester transfer protein (CETP) on multiple organ systems through modification of lipoprotein metabolism.
Recent Findings: Results from observational studies, Mendelian randomization analyses, and randomized clinical trials support the potential of CETP inhibition to reduce atherosclerotic cardiovascular disease (ASCVD) risk through a reduction of apolipoprotein B-containing lipoproteins. In contrast, raising high-density lipoprotein (HDL) particles, as previously hypothesized, did not contribute to ASCVD risk reduction. There is also an expanding body of evidence supporting the benefits of CETP inhibition for safeguarding against other conditions associated with aging, particularly new-onset type 2 diabetes mellitus and dementia, as well as age-related macular degeneration, septicemia, and possibly chronic kidney disease. The latter are likely mediated through improved functionality of the HDL particle, including its role on cholesterol efflux and antioxidative, anti-inflammatory, and antimicrobial activities.
Summary: At present, there is robust clinical evidence to support the benefits of reducing CETP activity for ASCVD risk reduction, and plausibility exists for the promotion of longevity by reducing risks of several other conditions. An ongoing large clinical trial program of the latest potent CETP inhibitor, obicetrapib, is expected to provide further insight into CETP inhibition as a therapeutic target for these various conditions.
the classcognitiondiabeteslongevityobicetrapib
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.